-
Innovation Ranking
NewInnovation Ranking – Oil-Dri Corporation of America
Oil-Dri Corporation of America (Oil-Dri) is a manufacturer and supplier of sorbent products. The company offers granular clay absorbents, universal absorbent products, hazmat, oil only absorbents, socks and boom, spill kits, sweeping compounds, and secondary containment products. Oil-Dri universal absorbent products include universal pads, universal rolls, universal socks and pillows, and universal spill kits. The company's universal rolls can be used for all fluids including acids, bases, oils, hydraulic fluids, and general spills. Oil-Dri’s sorbent products are produced from clay...
-
Product Insights
Dries Meganiese Dienste (Aj Van Wyk) Mine
The Dries Meganiese Dienste (Aj Van Wyk) Mine is a diamond mine in South Africa. It is currently in operation. Empower your strategies with our Dries Meganiese Dienste (Aj Van Wyk) Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval Analysis for Varicellovirus Infections
Overview How likely is it that the drugs in Varicellovirus Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varicellovirus Infections Overview Varicella-like viruses are cell-associated herpesviruses of the genus Varicellovirus,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RiMO-301 in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ID-93 in Pulmonary Tuberculosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ID-93 in Pulmonary Tuberculosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ID-93 in Pulmonary Tuberculosis Drug Details: ID-93 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemolizumab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemolizumab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemolizumab in Atopic Dermatitis (Atopic Eczema) Drug Details: Nemolizumab (Mitchga)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemolizumab in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemolizumab in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemolizumab in End-Stage Kidney Disease (End-Stage...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemolizumab in Prurigo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemolizumab in Prurigo report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemolizumab in Prurigo Drug Details: Nemolizumab (Mitchga) is monoclonal antibody against it is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab in Ductal Carcinoma In Situ report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab in Ductal Carcinoma In Situ Drug Details: Trastuzumab (Herceptin,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab in Non-Small Cell Lung Cancer Drug Details: Trastuzumab (Herceptin,...